Based on LEAVO trial, bevacizumab was not noninferior to aflibercept and ranibizumab for ME patients, and among the three injections no differences in QUALY. therefore bevacizumab would be most common Anti-VEGF, due its low cost compared to other. https:/
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Sec… https://t.co/EEe5IgQDOr
One of the best conducted trials in UK. No obvious winners. Intravitreal Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema From Retinal Vein Occlusion https://t.co/nxXjzXmvWx
📰 Двойное слепое РКИ показало, что афлиберцепт и ранибизумаб в среднем одинаково лечат макулярный отек, вызванный тромбозом центральной вены сетчатки. Бевацизумаб в сравнении с ранибизумабом не вселил такой уверенности (может быть так же, а может и хуже) h
RT @eye_kelly: .@JAMAOphth #LEAVO study results online at https://t.co/K9khUMdWfl Effectiveness of Ranibizumab vs Aflibercept vs Bevacizu…
.@JAMAOphth #LEAVO study results online at https://t.co/K9khUMdWfl Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion ( #CRVO ) Pleased @boltonnhsft was one of the #clinicaltrials s
Intravitreal Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema From Retinal Vein Occlusion by @JAMAOphth https://t.co/GWAsM1rGa5
Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to CRVO https://t.co/4EGbeZbjin
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. https://t.co/sDI9Cr4lRr